MOMENT

Trial Info

Status: Open

Specialty: Lung

Date Opened: 16/03/2023

Planned Close Date: 30/09/2026

Sponsor: MSD - Merck

Principal Investigator: Dr Pavel Bezecny

Study Title: Disease Registry on Patients with Advanced Non-small Cell Lung Cancer(NSCLC) Harboring METex14 Skipping Alterations MOMENT (Met nOn sMall cEll caNcer regisTry)

Trial Description

Patients who have advanced non-small cell lung cancer (NSCLC) with the genetic defect called ‘METex14 skipping alterations’ and are being treated with currently approved anti-cancer therapies can be included in the registry.

Inclusion Criteria

1. Signed ICF

2. Advanced stage (stages IIIB-IV) NSCLC (all histologies)

3. Confirmed METex14 skipping alterations (by valid assay)

4. Starting or already treated with systemic therapy

Exclusion Criteria

Enrolled in a clinical trial

Contacts

Clinical Trials Coordinator: Samuel Almond (x8475) Samuel.Almond@lthtr.nhs.uk or Zainab Chauhan (x8475) Zainab.Chauhan@lthtr.nhs.uk

Nurse oversight: Amanda Cook

Link to EDGE

Back